Compare ARCB & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCB | DVAX |
|---|---|---|
| Founded | 1923 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | ARCB | DVAX |
|---|---|---|
| Price | $76.30 | $10.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $90.91 | $26.50 |
| AVG Volume (30 Days) | 357.9K | ★ 1.5M |
| Earning Date | 01-30-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $4,039,115,000.00 | $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | $3.87 | $15.85 |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $55.19 | $9.20 |
| 52 Week High | $111.80 | $14.63 |
| Indicator | ARCB | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 48.59 |
| Support Level | $68.75 | $10.71 |
| Resistance Level | $77.93 | $11.00 |
| Average True Range (ATR) | 2.78 | 0.26 |
| MACD | 1.56 | -0.06 |
| Stochastic Oscillator | 91.81 | 22.63 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.